Although previous studies showed that IGF2BP3 promoted the aggressive phenotypes of CRC cells [23] and regulated cell cycle and angiogenesis in colon cancer [24], the molecular mechanisms of IGF2BP3 in CRC progression and drug resistance remain largely unclear. Here, IGF2BP3 is linked to malignant colon neoplasm.